Thu. 9 May 2024, 4:22pm ET
Benzinga
Earnings, Earnings Beats, News
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.83) per share which beat the analyst consensus estimate of $(2.88) by 1.74 percent. This is a 27.99 percent increase over losses of $(3.93) per share from the same period last year. The company reported quarterly sales of $569.000 thousand which beat the analyst consensus estimate of $176.667 thousand by 222.08 percent. This is a 180.30 percent increase over sales of $203.000 thousand the same period last year.